Welcome to our dedicated page for Blueprint Medicines news (Ticker: BPMC), a resource for investors and traders seeking the latest updates and insights on Blueprint Medicines stock.
Blueprint Medicines Corp. reports biopharmaceutical developments in allergy/inflammation and oncology/hematology, with recurring updates centered on AYVAKIT®/AYVAKYT® (avapritinib) for systemic mastocytosis. Company news covers clinical data presentations, long-term safety and efficacy findings, real-world disease-burden research, reimbursement and commercialization updates, and operating results tied to product revenue.
Additional updates describe the company’s mast cell disease pipeline, including BLU-808 and elenestinib, as well as corporate presentations, financial guidance, material agreements, capital-structure matters, leadership changes and other business updates.
Blueprint Medicines reported strong first quarter 2024 results, generating $92.5 million in AYVAKIT net product revenues and raising full-year revenue guidance to $390-$410 million. The company is on track to submit an IND for BLU-808 in Q2 to strengthen its presence in allergy and inflammation. Blueprint Medicines continues to advance its pipeline, with key developments in mast cell disorders and HR+/HER2- breast cancer. Financially, the company anticipates growth in global product revenues, decreased operating expenses, and a strong cash position.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.